WallStreetZenWallStreetZen

NASDAQ: TRML
Tourmaline Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for TRML

Based on 4 analysts offering 12 month price targets for Tourmaline Bio Inc.
Min Forecast
$41.00+12.45%
Avg Forecast
$49.75+36.45%
Max Forecast
$65.00+78.28%

Should I buy or sell TRML stock?

Based on 4 analysts offering ratings for Tourmaline Bio Inc.
Strong Buy
Strong Buy
4 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TRML stock forecasts and price targets.

TRML stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-12-15
lockedlocked$00.00+00.00%2023-11-17
lockedlocked$00.00+00.00%2023-10-31
lockedlocked$00.00+00.00%2023-10-25

1 of 1

Forecast return on equity

Is TRML forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.74%

Forecast return on assets

Is TRML forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

TRML revenue forecast

What is TRML's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$33.8M
Avg 2 year Forecast
$132.6M
Avg 3 year Forecast
$307.9M

TRML vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRML$36.46$49.75+36.45%Strong Buy
YMAB$17.01$21.00+23.46%Buy
OLMA$13.48$22.00+63.20%Strong Buy
IGMS$12.81$15.67+22.30%Buy
ALLO$4.36$8.67+98.78%Strong Buy

Tourmaline Bio Stock Forecast FAQ

Is Tourmaline Bio Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: TRML) stock is to Strong Buy TRML stock.

Out of 4 analysts, 4 (100%) are recommending TRML as a Strong Buy, 0 (0%) are recommending TRML as a Buy, 0 (0%) are recommending TRML as a Hold, 0 (0%) are recommending TRML as a Sell, and 0 (0%) are recommending TRML as a Strong Sell.

If you're new to stock investing, here's how to buy Tourmaline Bio stock.

What is TRML's revenue growth forecast for 2027-2029?

(NASDAQ: TRML) Tourmaline Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 52.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.05%.

Tourmaline Bio's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast TRML's revenue for 2027 to be $687,381,846, with the lowest TRML revenue forecast at $317,253,160, and the highest TRML revenue forecast at $1,077,847,273. On average, 5 Wall Street analysts forecast TRML's revenue for 2028 to be $2,696,651,857, with the lowest TRML revenue forecast at $549,092,007, and the highest TRML revenue forecast at $4,136,493,119.

In 2029, TRML is forecast to generate $6,261,601,207 in revenue, with the lowest revenue forecast at $2,216,704,769 and the highest revenue forecast at $12,319,590,963.

What is TRML's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: TRML) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is TRML's Price Target?

According to 4 Wall Street analysts that have issued a 1 year TRML price target, the average TRML price target is $49.75, with the highest TRML stock price forecast at $65.00 and the lowest TRML stock price forecast at $41.00.

On average, Wall Street analysts predict that Tourmaline Bio's share price could reach $49.75 by Dec 15, 2024. The average Tourmaline Bio stock price prediction forecasts a potential upside of 36.45% from the current TRML share price of $36.46.

What is TRML's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: TRML) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.